Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959282 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
NCT01959282 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 219 participants.
The verdict
NCT01959282, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG JNJ-54781532 25 mg once daily
- DRUG JNJ-54781532 75 mg once daily
- DRUG JNJ-54781532 150 mg once daily
- DRUG JNJ-54781532 75 mg twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2013-11-15 |
| Est. Completion | 2015-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959282
The ClinicalTrials.gov registry entry for NCT01959282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01959282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959282 about?
NCT01959282 is a clinical study titled "A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis". The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT01959282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2013-11-15. Estimated completion is 2015-12-05.
What interventions are being tested in trial NCT01959282?
The interventions under investigation include: Placebo (DRUG), JNJ-54781532 25 mg once daily (DRUG), JNJ-54781532 75 mg once daily (DRUG), JNJ-54781532 150 mg once daily (DRUG), JNJ-54781532 75 mg twice daily (DRUG).
Who is sponsoring clinical trial NCT01959282?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.